PMID- 30460780
OWN - NLM
STAT- MEDLINE
DCOM- 20190729
LR  - 20190729
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 22
IP  - 3
DP  - 2019 Mar
TI  - Long-term efficacy of repeated sodium hyaluronate injections in adult patients 
      with Kashin-Beck disease of the knee.
PG  - 392-398
LID - 10.1111/1756-185X.13435 [doi]
AB  - AIM: To prospectively evaluate the long-term efficacy and safety of repeated 
      sodium hyaluronate injections for the treatment of knee pain due to Kashin-Beck 
      disease (KBD). METHODS: A total of 85 patients with KBD-based knee pain were 
      treated with two cycles of a 5-week course of sodium hyaluronate and received 
      clinical assessments with a follow-up period of 24 months after the first cycle. 
      The primary efficacy measure was the visual analogue scale (VAS) pain score. The 
      second efficacy measure included the Western Ontario and McMaster Universities 
      Osteoarthritis Index (WOMAC) scores; and the patients' and physicians' global 
      assessments. Tolerability was evaluated based on adverse events (AEs). RESULTS: 
      Seventy-one patients (83.5%) completed the final study. The VAS was significantly 
      reduced from 65.06 +/- 12.21 mm (mean +/- standard deviation [SD]) at baseline to 
      30.17 +/- 11.92 mm at 6 months and was maintained for 24 months (35.79 +/- 7.92 mm, 
      P < 0.01 vs baseline). This finding was supported by the secondary variables (the 
      WOMAC A, B and C scores; the total WOMAC scores; and the global assessments of 
      the patients and their physicians at months 6, 12, 18 and 24). The overall 
      incidence of AEs during the first and second cycles was 8 (9.4%) and 7 patients 
      (8.2%), respectively. No serious AEs were reported. CONCLUSIONS: Repeated once 
      yearly cycles of intra-articular sodium hyaluronate injections may improve knee 
      KBD symptoms during the inbetween cycle period as well as exert a significant 
      carry-over effect for at least 1 year after the repeated cycle. Other randomized 
      double-blind studies are needed to confirm the findings from our study.
CI  - (c) 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons 
      Australia, Ltd.
FAU - Tang, Xin
AU  - Tang X
AUID- ORCID: 0000-0002-5027-1189
AD  - Orthopedic Department, West China Hospital, Sichuan University, Chengdu, China.
FAU - Zhou, Zong-Ke
AU  - Zhou ZK
AD  - Orthopedic Department, West China Hospital, Sichuan University, Chengdu, China.
FAU - Shen, Bin
AU  - Shen B
AD  - Orthopedic Department, West China Hospital, Sichuan University, Chengdu, China.
FAU - Kang, Peng-de
AU  - Kang PD
AD  - Orthopedic Department, West China Hospital, Sichuan University, Chengdu, China.
FAU - Pei, Fu-Xing
AU  - Pei FX
AD  - Orthopedic Department, West China Hospital, Sichuan University, Chengdu, China.
FAU - Li, Jian
AU  - Li J
AD  - Orthopedic Department, West China Hospital, Sichuan University, Chengdu, China.
LA  - eng
GR  - 2007BAI 25B04/China National Science & Technology Pillar Program during the 
      eleventh 5-year plan period/
GR  - 2014SZ0023-1/Science Plan of Sichuan Province/
GR  - 81101388/National Natural Science Foundation of China/
PT  - Clinical Trial
PT  - Journal Article
DEP - 20181120
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Viscosupplements)
RN  - 9004-61-9 (Hyaluronic Acid)
MH  - Adult
MH  - Aged
MH  - Arthralgia/diagnosis/*drug therapy
MH  - China
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Hyaluronic Acid/*administration & dosage/adverse effects
MH  - Injections, Intra-Articular
MH  - Kashin-Beck Disease/diagnosis/*drug therapy
MH  - Knee Joint/diagnostic imaging/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Time Factors
MH  - Treatment Outcome
MH  - Viscosupplementation/adverse effects/*methods
MH  - Viscosupplements/*administration & dosage/adverse effects
OTO - NOTNLM
OT  - Kashin-Beck
OT  - disease knee
OT  - efficacy
OT  - sodium hyaluronate
EDAT- 2018/11/22 06:00
MHDA- 2019/07/30 06:00
CRDT- 2018/11/22 06:00
PHST- 2016/12/01 00:00 [received]
PHST- 2017/05/09 00:00 [revised]
PHST- 2018/09/28 00:00 [accepted]
PHST- 2018/11/22 06:00 [pubmed]
PHST- 2019/07/30 06:00 [medline]
PHST- 2018/11/22 06:00 [entrez]
AID - 10.1111/1756-185X.13435 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2019 Mar;22(3):392-398. doi: 10.1111/1756-185X.13435. Epub 2018 
      Nov 20.